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Abstract 
This review presents natural products from cyanobacteria. Several classes of 
secondary metabolites are highlighted. Toxic metabolites from these prokaryotic 
photosynthetic organisms include compounds such as microcystin, anatoxin and 
saxitoxin, which display hepatotoxicity and neurotoxicity. Their potential as drugs in 
cancer therapy is discussed based on the cryptophycin class of potent cytotoxic 
agents. The next part of this review highlights iron chelators from cyanobacteria, 
including schizokinen, synechobactin and anachelin. The biogenesis of anachelin is 
investigated as its mechanism of iron acquisition. Several indole alkaloids are then 
reviewed, from simple carbolines such as bauerines and nostocarboline to complex 
polycyclic structures such as hapalindole, welwitindolinone and ambiguine. The 
latter compounds present fascinating structure combined with powerful bioactivities 
and interesting biogenetic pathways. In the last part, protease inhibitors from 
cyanobacteria are discussed (cyanopeptolins, micropeptin and oscillapeptin) and 
their structure/activity relationships and selectivity for trypsin / chymotrypsin are 
presented. All these examples highlight the large structural variety of cyanobacterial 
metabolites combined with powerful biological activities. Cyanobacteria can thus be 
considered a prime source both for novel bioactive compounds and for leads for 
drugs. 
Keywords 
Natural products – Isolation – Structure determination – Biosynthesis – Medicinal 
chemistry – Total synthesis 
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1 Introduction 
Cyanobacteria are among the most successful and oldest life forms still 
present on earth. These prokaryotic photoautotrophs populate habitats as diverse as 
soil, marine and freshwater environments, rocks (endolithic), plants or animals (as 
endosymbionts) to ice. This vast variety of different ecological niches, in some of 
which tough competition for nutrients rules, requires successful adaptation to vastly 
different conditions. In order to adapt to these surroundings, cyanobacteria evolved 
to produce a wide variety of different secondary metabolites.[1-6] In particular 
cyanobacteria from marine and freshwater sources produce many metabolites which 
possess powerful biological activities.[1,3] This review will present different classes of 
secondary metabolites generated by cyanobacteria, will highlight their complex 
structures and powerful bioactivities and will discuss their relevance to human health 
and society. 
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2 Toxic metabolites from cyanobacteria 
The class of cyanobacterial secondary metabolites that recently received wide 
attention from different scientific communities as well as the general public, are 
cyanobacterial toxins or cyanotoxins.[5-7] One of the best studied classes of 
cyanobacterial toxins are the microcystins, modified peptides produced by a large 
variety of different cyanobacteria such as Anabaena, Microcystis, Hapalasiphon, 
Nostoc and Oscillatoria.[8-13] The general structure of microcystins is described by 
cyclo(-D-Alal1-Xaa2-D-MeAsp3-Yaa4-Adda5-D-Glu6-Mdha7-), whereas the amino acids 
Xaa2 and Yaa4 are highly variable and determine the suffix in the nomenclature of 
microcystins.[14] For example, the microcystin shown in Fig. (1) is called Microcystin 
LR (Xaa2 = Ala, Yaa4 = Arg).[10] So far, more than 50 different variants of 
microcystins have been found, all featuring the !-amino acid (2S,3S,8S,9S)-3-
amino-9-methoxy-2,6,8-trimethyl-10-phenyldecy-4(E),6(E)-dienoic acid abbreviated 
as Adda.[9,10] This amino acid was shown to be essential for the biological activity of 
microcystin via the covalent modification of proteins.[10,15,16] Microcystins are highly 
active against protein phosphatase 1 and 2A.[17,18] These proteins are essential for 
many signal transduction pathways of eukaryotic cells such as programmed cell 
death (apoptosis).[19,20] This enzyme inhibitory activity is also responsible for the 
toxicity of microcystins to grazers and thus point to their ecological role as 
deterrence chemicals in aquatic ecosystems.[21,22] Recently, microcystins caused 
great concerns to human health organizations. Due to the known hepatotoxicity of 
microcystins, elevated levels of liver cancer were related to the presence of 
microcystin in drinking water.[7] Actually, Microcystis is the most prevalent 
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cyanobacterial genus to be suspected with human poisoning.[23] As a consequence, 
the World Health Organization (WHO) has set threshold values for microcystin 
concentrations in drinking water.[24] 
Fig. (1). Microcystin LR, a cyanobacterial toxin from Microcystis aeruginosa. 
 
Another class of important cyanobacterial toxins includes alkaloids such as 
the anatoxin and saxitoxin Fig. (2).[4,6,9,11,12] Anatoxins (originally called fast death 
factors) are neurotoxins and affect the nervous system, the skin (swimmer!s itch) or 
the gastro internal tract.[25-27] In high doses, anatoxins lead to death due to 
respiratory failure. Whereas anatoxin-a is a bicylic amine, the more complex 
anatoxin-a(s)[28-31] features an interesting phosphate ester of a cyclic N-
hydroxyguanidine motif. These compounds act upon acetylcholinesterase[28] and 
thus lead to toxic effects and ultimately death in higher organisms.[29] 
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Fig. (2). Anatoxin, anatoxin-a(s) and saxitoxin, potent cyanobacterial 
neurotoxins. 
 
Saxitoxin,[32,33] originally identified from axenic cultures of the dinoflagellate 
Gonyaulax catenella,[34] is also produced by several cyanobacteria.[35] This tricyclic 
alkaloid, structurally related to tetrodotoxin,[36,37] blocks neuronal transmission by 
binding to Na channels in nerve cells.[38] The sodium gradient is thus stopped, which 
leads to muscle paralysis and thus death in mammals.[38] Saxitoxins can be a cause 
of paralytic shellfish poisoning in humans consuming contaminated shellfish, as 
these toxins are bioaccumulated by marine molluscs and crustacaens.[39]  
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Fig. (3). Cylindrospermopsin, a toxin from a variety of cyanobacteria 
 
Cylindrospermopsin, isolated from a variety of freshwater cyanobacteria such 
as Cylindrospermospsis, Anabaena bergii and others,[40-42] can also be considered a 
threat to drinking water supplies Fig. (3).[43,44] This alkaloid possesses an interesting 
structure merging an uracil fragment to a tricyclic guanidinium moiety.[41] Poisonings 
of cattle livestock and even humans have been attributed to the occurrence of toxic 
Cylindrospermospsis blooms in lakes and thus to cylindrospermopsin.[43,44] The 
mode of action of this alkaloid was proposed to involve DNA intercalation and 
followed by strand cleavage.[45] 
Cyanobacteria have been recently considered a source for metabolites with 
great potential for clinical use.[46-49] The most prominent member of a cyanobacterial 
product with potent anticancer properties is cryptophycin, originally isolated as 
fungicide in 1990 from a Nostoc strain Fig. (4).[50] Its structure is typical for 
cyanobacterial metabolites, as it is composed out of a polyketide fragment, a 
modified D-!-amino acid, a "-amino acid and a hydroxyacid forming a depsipeptide. 
While cryptophycin was first identified for its potent antifungal activity against 
Cryptococci,[50] it was later abandoned due to its notable toxicity. Later, Moore and 
coworkers isolated the same compound from another Nostoc strain[51] and 
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determined powerful cytotoxicity against tumor cell lines with IC50 value in the order 
of 10 pM.[52,53] In addition, cryptophycin was not a substrate for the P-glycoprotein 
efflux pump, as activity was found against both drug-sensitive and drug–resistant 
tumor cell lines.[53] This cyanobacterial peptide polyketide hybrid induces apoptosis 
by blocking the cell cycle at the G2/M phase apparently via inhibition of tubulin 
polymerization.[54] The mode of action of cryptophycin combined with its extreme 
potency (up to 1000 fold greater than taxol), led to its clinical evaluation as well as 
structure/activity relationships (SAR).[55] 
 Fig. (4). Cryptophycin 1 and 52, potent antitumor agents isolated from 
cyanobacteria. 
 
Over the years, more than 25 different cryptophycins were isolated from 
natural sources allowing for detailed SAR studies.[55] Interestingly, the most 
abundant compound (220 mg cryptophycin 1 were isolated from 50 g algae), was 
the most cytotoxic entity. The epoxide was essential for activity, as were all 
structural features of the polyketide fragment.[55] Modification of the aromatic ring of 
the D-amino acid were tolerated, whereas replacement with L-amino acids led to a 
reduction of activity by five orders of magnitude.[55] In order to complement the SAR 
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of the natural isolates, researchers both in academia and in industry (Eli Lilly) 
embarked on the synthesis of hundreds of analogs, allowing for a detailed 
understanding of the structural requirements for the biological activity of 
cryptophycins.[55] Cryptophycin 52 was found to be more stable towards hydrolysis 
and was thus selected as the main candidate for clinical development by Eli Lilly 
(LY355703).[56,57] While this compound passed phase I clinical studies,[56,57] there is 
little data in the literature concerning phase II studies.[58] 
Borophycin is a complex boron containing polyketide, isolated in 1994 by 
Moore and coworkers from Nostoc linckia[59] and later from Nostoc spongiaeforme 
Fig. (5).[60] This metabolite displayed promising antitumor activity against standard 
cancer cell lines (MIC 0.066 mg/mL, LoVo and 3.3 mg/mL KB).[59] The structure was 
assigned by spectroscopic methods and both configuration and constitution 
unambiguously established by single crystal X-Ray diffraction. The structure can be 
regarded as a dimeric macrodiolide, with a borate linking the two strands. Its 
structure strongly resembles boromycin from Streptomyces antibioticus, isolated in 
1969 by Prelog, Zähner, Keller-Schierlein and coworkers[61] and structure 
determination by Dunitz, Prelog and coworkers,[62] aplasmomycin from Streptomyces 
griseus[63,64] and tartrolon from Sorangium cellulosum.[65]  
10 
 Fig. (5). Borophycin from cyanobacteria and boromycin from streptomyces. 
 
 
Borophycin remains as the only metabolite isolated so far from cyanobacteria 
serving as a ligand to a semi-metal. In the next chapter, an overview of small 
cyanobacterial metabolites as ligands for iron will be presented. 
3. Iron chelators from cyanobacteria 
Cyanobacteria are considered to be among the oldest organisms on earth, 
populating this planet since over 2.5 billion years. Over 2 billions years ago, these 
organisms are thought to release oxygen in earth!s atmosphere thus changing from 
a reductive to an oxidative environment as it is present today.[66,67] This change had 
dramatic consequences as almost all life forms were forced to adapt to these 
oxidative conditions or to become extinct. Moreover, the change from a reductive to 
an oxidative atmosphere had the detrimental side effect that the soluble and 
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prevalent Fe(II) salts were oxidized to the corresponding Fe(III) oxide hydrates, 
which are almost insoluble.[68] Due to this extremely low bioavailability of iron, the 
acquisition, transport and storage of Fe became a central challenge for every 
organism.[68] Microorganisms thus evolved sophisticated strategies for Fe 
sequestering involving small organic ligands, so called siderophores.[69,70] In fact, 
many siderophores from bacteria have been isolated which can be clustered in three 
different structural types.[69,70] 
The first group is the catecholate siderophores exemplified by enterobactin 
from enterococci Fig. (6).[71,72] Its structure is characterized by a C3 symmetric 
trilactone ring, of which the exocyclic N atoms are acylated by dihydroxybenzoic 
acid. These ligands bind Fe with exceptionally high binding constants of up to 
1047.[73] The release of iron in the cell is accomplished by protonation of the 
catecholate, by enzymatic hydrolysis of the lactone ring or by reduction of Fe(III) to 
Fe(II).[71] 
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 Fig. (6). The three main structural classes of bacterial siderophores. 
Another class of siderophores is represented by hydroxamate siderophores 
exemplified by desferrioxamine (DFO), isolated by Prelog and collaborators fifty 
years ago.[74-76] Key elements are hydroxamic acid units which can chelate to Fe(III) 
in a bidentate way. The binding constants of DFO have been determined to be 
between 1020 and 1030, depending on the structure and on the pH.[77,78] DFO is a drug 
currently used to treat iron overload.[79] Iron is so precious to humans that men have 
no means of secreting excess iron out of the body.[80] Excess iron leads to oxidative 
stress followed by tissue damage and, ultimately, death.[81] Moreover, 
hemochromatosis is the most prevalent genetic disorder in Europe with 1 out of 20 
carrying the mismatched gene, [82] and this disease is directly linked to high iron 
levels. Iron overload can only be cured by either phlebotomy or treatment with 
DFO.[83] The drawback of DFO is that it needs to be administered for 6 days for at 
least 12 hours intravenously due to poor pharmacokinetics. Patient compliance is 
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thus a significant problem. Novartis has recently introduced a small molecule for 
treating iron overload (ICL-670).[79] 
The last class of iron chelators are the oxazoline/thiazoline catecholates 
exemplified by vibriobactin from Vibrio cholerae[84] or yersiniabactin from Yersinia 
pestis.[85-87] In recent years, research on these virulence factors surged in order to 
better understand bacterial infections.[88,89] Moreover, interesting new therapeutic 
approaches to treat such diseases have been developed based on siderophores. 
Examples feature the so-called “trojan horses” developed in the research groups of 
Braun,[90] Miller, [91,92] and Budzikiewicz.[93] The design of these compounds involves 
the conjugation of an antibiotic fragment to a siderophore, a principle which nature 
also uses in antibiotics such as ferrimycin,[94,95] albomycin[96-98] or salmycin.[99] As 
bacteria recognize extracellular siderophores and have developed active 
mechanisms for their uptake, the antibiotic fragment is transported inside the 
bacteria. Therefore, these siderophore/antibiotics conjugates are highly active. 
However, since a key pathway of bacterial survival, i.e. iron acquisition, is targeted, 
resistance to these compounds quickly develops.[100]  
 Fig. (7). Cyanobacterial siderophores derived from citric acid. 
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Whereas bacterial siderophores have been actively studied for decades, 
there is much less known about cyanobacterial iron chelators. This is surprising, as 
cyanobacteria probably caused the transformation of a reductive atmosphere to an 
oxidative one and thus rendered the uptake of Fe(III) a central challenge to every 
organism.[66,67] Another problem is that cyanobacteria frequently populate marine and 
freshwater habitats and are among the most important primary producers. In such 
environments, complex siderophores, which are costly to make by the organism 
involving many enzymes and pathways), are lost by dilution when secreted. 
Therefore, it was assumed for a long time that only small and simple organic 
molecules such as simple hydroxamic acids or citrate would be used. Their benefit 
would include ease of preparation with the drawback of poorer iron chelation. 
The first report on a cyanobacterial siderophore was schizokinen from the 
freshwater Anabaena PCC 7120 Fig. (7).[101-103] This compound, originally isolated 
from the terrestrial bacterium Bacillus megaterium,[104,105] is a citrate derivative of 
which two carboxylate groups are amidated with an acetyl hydroxamic amine. In 
2005, the synechobactins were isolated from a coastal marine cyanobacterium, 
Synechococcus PCC 7002 and demonstrated to act as siderophores.[106] These 
compounds can be considered as derivatives of schizokinen, with one of the 
hydroxamic acids replaced by a long fatty acid. The authors suggest that this 
amphiphilic structure helps to anchor the siderophore into the membrane of 
cyanobacterium and thus prevents its loss by dilution in marine environments. This 
notion is supported by several amphiphilic siderophores from marine bacteria such 
as marinobactin E, aquachelin D and amphibactin D, which all carry a long 
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hydrophobic chain.[107] The citrate core of both schizokinen and synechobactin are 
also found in petrobactin.[108] 
The first complex siderophore, and only the second siderophore to be 
isolated from cyanobacteria were the anachelins, produced by Anabaena cylindrica 
1403-2a. This blue-green alga, originally isolated in 1939 from a pond in Surrey, is 
forming filaments that contain heterocysts, where N2 fixation can occur. The 
filaments of A. cylindrica form biofilms or cyanobacterial mats that are attached to 
surfaces Fig. (8). Upon longer growth and concomitant oxygen production, the 
cyanobacterial mats detach from the surface forming a cyanobacterial bloom.  
 Fig. (8). A culture of Anabaena cylindrica 1403-2a showing how this filamentous 
cyanobacterium forms biofilms attached to surfaces. 
16 
Two anachelins were isolated from this Anabaena by Budzikiewicz, Walsby 
and coworkers and reported in 2000: Anachelin H containing a terminal salicylamide 
and anachelin 1, terminated by an oxazoline ring Fig. (9).[109] These compounds are 
structurally complex metabolites, which contain fragments of different biosynthetic 
origin. The salicylate unit, which can emanate out of a polyketide pathway or be 
derived from the chorismate pathway, a mixed polyketide/amino acid fragment, a 
tripeptide part and an unusual tetrahydroquinolinium alkaloid fragment. Thus, 
anachelin can be considered natural product hybrid. [110] While the constitution was 
published, it was not possible for this group to determine the absolute or relative 
configuration of any of the stereogenic centers.  
Fig. (9). Anachelin H and anachelin 1, isolated from Anabaena cylindrica 
1403-2a. 
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Subsequently, Murakami and coworkers reported the isolation and structure 
elucidation of anachelin 1 and additional isomers Fig. (10).[111] In addition to the 
terminal oxazoline, the authors also obtained anachelin 2 featuring the oxazoline 
ring from C(5)-O to the C(6)-N. Moreover, two related esters were obtained. The 
authors were also successful in determining the absolute configuration of the 
tripeptide fragment thus establishing the sequence as L-Thr-D-Ser-L-Ser. The 
configuration of the polyketide fragment as well as the alkaloid part remained 
unassigned. 
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 Fig. (10). Anachelin 1, anachelin 2 and related esters. 
 
Out of the five anachelins isolated, the question can be raised which of the 
compounds are present in nature and which compounds could be isolation artifacts. 
Budzikiewicz, Walsby and coworkers always obtained mixtures of anachelin H and 
anachelin 1, and were never able to isolation anachelin 1 in pure form.[109] Moreover, 
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these authors stated that the oxazoline ring in anachelin 1 is prone to hydrolysis 
upon standing in aqueous solution.[109] This experimental evidence thus suggests 
that the biologically active compound is anachelin H, and that the oxazoline of 
anachelin 1 and anachelin 2 are formed upon dehydrating conditions. This could be 
the case when extracts are purified by using HPLC with trifluoracetic 
acid/acetonitrile/water mixtures. The lyophilization of fractions containing anachelin 
H could lead to acid catalyzed dehydration Fig. (11) top.  
 Fig. (11). Possible pathways for the formation of anachelin 1, anachelin 2 
and the related esters from anachelin H. 
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The formation of the esters could be easily explained by an N, O-acyl shift of 
the salicylamide under slightly acidic conditions. This shift would be favored due to 
the protonation of the amino group in acidic medium. This would provide an 
explanation why Murakami and coworkers did not obtain anachelin H, but instead 
the isomeric esters.[111] N, O-acyl shifts are frequently observed in peptides and a 
well-known example is the formation of iso-cyclosporin derived from cyclosporin via 
an N, O-acyl shift of the MeBmt amino acid.[112-116]  This migration readily occurs 
under acidic conditions and is fully reversible upon the addition of base.[116] Last, 
anachelin is the siderophore of an aquatic freshwater siderophore, which should be 
resistant to facile hydrolysis. This requirement adds further support to the role of 
anachelin H, as anachelin 1 was found to be prone to hydrolysis. All these reasons 
provide support for the hypothesis that anachelin H constitutes the actual 
siderophore, and that anachelin 1 and 2, as well as the related esters would be 
considered derivatives. 
 Fig. (12). The absolute configuration of anachelin 1 as determined by 
Murakami and coworkers.[117] 
In the initial isolation report, Murakami and coworkers were not able to 
determine the absolute configuration of the polyketide and alkaloid fragments.[111] In 
a subsequent publication, Murakami and coworkers established the relative and 
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absolute configuration of anachelin via degradation and spectroscopic analysis and 
published their analysis in 2004 Fig. (12).[117] We have independently established the 
relative and absolution configuration via a stereodivergent synthesis. [118] 
The tetrahydroquinoliunium chromophore of anachelin is highly unusual, and 
its biogenesis is unknown. We have postulated a biogenetic hypothesis Fig. (13), [119] 
that was used as a blueprint for a total synthesis of this metabolite. [118] We 
hypothesized that the unusual chromophore is biogenetically derived from a C-
terminal tyrosine. Reductive amination and methylation would give the 
dimethyltyrosinamine precursor. Hydroxylation followed by oxidation would lead to 
the ortho quinone that can react in an intramolecular aza annulation reaction that 
would furnish, after tautomerization, the anachelin chromophore. In order to test this 
hypothesis in the chemical laboratory, and to evaluate potential enzyme catalysts of 
this transformation, we prepared the model precursor as shown in Fig. (14).  
 
 Fig. (13). Biogenetic proposal for the formation of the anachelin chromophore. 
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Fig. (14). Biomimetic formation of the anachelin chromophore by the enzyme 
tyrosinase. 
 
 
Exposure of this diamine to tyrosinase, an ubiquitous enzyme involved in tyrosine 
and DOPA oxidation, gave rise to the anachelin chromophore. The formation of this 
compound is observed spectroscopically within minutes, and the product anachelin 
chromophore could be isolated and characterized on a preparative scale. These 
experiments provide a clear rationale for the involvement of this enzyme in the 
biogenesis of the anachelins. [120] 
Our investigations on the solution structure,[121] biogenesis,[120] synthesis,[118,119] and 
mode of action[122] of anachelin led to a thorough molecular understanding of the 
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different facets of this compound. This knowledge also allowed for the application in 
a totally different field, i.e. surface modification in materials science. The 
predominant physical form of iron in marine and freshwater environments are iron 
oxide hydrates, which are solid minerals. In addition, iron ions are present in stones, 
rocks and minerals. Therefore, in order to apprehend iron ions, siderophores must 
recognize, bind and sequester iron from solid minerals. The first step of this process 
in binding of the siderophore to mineral surfaces. We therefore asked the question 
whether it is possible that anachelin binds to metal oxide surfaces. In order to test 
this hypothesis, we prepared the hybrid[110] of the anachelin chromophore and 
polyethylene glycol (PEG), which is frequently used to render surfaces resistant to 
the attachment of proteins. The resulting compound was clearly shown to efficiently 
bind to titanium oxide surfaces.[123] Thus, it has been shown that the anachelin 
chromophore recognizes metal oxide surfaces as found in minerals. This postulated 
first step in iron acquisition is thought to have large implications on the molecular 
understanding of iron acquisition of marine and freshwater organisms. 
 
4 Indole alkaloids 
Indole alkaloids are among the most frequently encountered classes of 
secondary metabolites in higher plants, and to a lesser extent, in microorganisms 
and animals.[124] Prominent examples include the ergot, iboga, pyrroloindole (i. e. 
physiostigmin), carboline (i. e. harmane, reserpine, yohimbin), aspidosperma and 
the strychnos alkaloids (i. e. strychin, brucin and curare).[124] In most of these cases, 
potent biological activities are associated with this structural framework, and the 
24 
isolation and structure elucidation of these compounds was of fundamental 
importance for the understanding of their mode of action for the development of 
related substances with beneficial effects. 
In contrast to this wealth of indole alkaloids from higher plants, there are 
much less cyanobacterial indole metabolites known so far. Larsen, Moore and 
Patterson of the University of Hawaii isolated the bauerines A-C from the terrestrial 
cyanobacterium Dichotrix baueriana GO-25-5 and determined their structure Fig. 
(15).[125] These compounds were found in the context of a screening program of 
hundreds of cyanophytes against Herpes simplex virus 2 (HSV-2), followed by 
bioassay-guided fractionation. While bauerine A was found to have an IC90 against 
HSV-2 of 2 µg/mL with a cytotoxicity of 3 µg/mL (LoVo), bauerine B was found to be 
less active. The most cytotoxic derivative was bauerine C with and IC50 (LoVo) of 
30ng/mL. 
 Fig. (15). Indole alkaloids isolated from cyanobacteria. 
 
In 2005, a report by Volk of the Universität Kiel, Germany appeared 
describing the identification of norharmane of Nodularia harveyana.[126] This is the 
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first identification of this compound from cyanobacteria. Norharmane is known in 
higher plants, bacteria and even in humans. Volk reported anticyanobacterial 
activity[127] of this compound against both filamentous and unicellular cyanobacteria, 
whereas no activity against green algae could be determined. [128,129] This is in 
agreement with earlier reports on the isolation of harmane from a marine 
Pseudomonas species by Murakami and coworkers, who also showed 
anticyanobacterial activity with green algae being unaffected.[130] These authors also 
suggested the use of harmane for the control of toxic algal blooms.[130] Given the 
known co-mutagenicity of harmane,[131,132] this suggested approach for algal bloom 
control could be questioned. The import plant hormone (phytohormane) auxin or 
indolo acetic acid was also recently identified in cyanobacteria of the genus 
Nostoc.[133] The production and release of such phytohormones by cyanobacteria 
living in symbiotic or parasitic environments could possess significant ecological 
consequences. 
 Fig. (16). Hapalindole A, isolated from Hapalosiphon fontinalis is structurally 
related to lysergic acid. 
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A class with structurally most remarkable indole alkaloids is based on 
hapalindoles and fischerindoles. Hapalindole A was isolated in 1984 from the blue 
green algae, Hapalosiphon fontinalis Fig. (16).[134] Interestingly, the isolation yield 
was rather high (0.58 % of dry cell weight). NMR spectroscopy complemented with 
UV and IR techniques were used to elucidate the fascinating structure of this 
metabolite containing a tetracyclic structure with isonitrile and chlorine 
substituents.[134] Hapalindole was reported to display antialgal and antimycotic 
properties, which point to the ecological role of this extracellular substance. In a 
subsequent publication, Moore and coworkers together with researchers from Eli 
Lilly reported the characterization of eighteen new hapalindole derivatives from the 
same organism.[135] All structures show the indole ring connected to a monoterpene 
unit, mainly with structural variation on the cyclohexane ring. Interestingly, the 
structure of hapalindole shares similarities to lysergic acid, a precursor to the ergot 
alkaloids.[134,135] 
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Fig. (17). The ambiguines and fischerindoles, members of the hapalindole 
family of indoles isolated from cyanobacteria. 
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Ambiguine isonitrile can be considered a more complex derivative of 
hapalindole, containing a densely functionalized, hexacyclic framework Fig. (17).[136] 
In fact, prenylation of the C(2) of hapalindole followed by ring closure and oxidation 
would result in ambiguine isonitrile D. This hypothesis is supported by the isolation 
of putative intermediates such as ambiguine isonitrile A. These complex indole 
metabolites display fungicidal activities against several fungi in a soft-agar disc-
diffusion assay.[136,137] Fischerindole L, isolated from the terrestrial blue-green alga 
Fischerella musciola, can be considered isomeric to hapalindole A, but possesses a 
hexahydroindeno[2,1-b]indole and isonitrile and chlorine functionalities. The isolation 
of fischerindole L could provide insights into the biosynthesis of these cyanobacterial 
indole alkaloids.[138] In fact, Moore and coworkers suggest that an isonitrile derived 
from tryptophan is fused to a geranyl pyrophosphate derivative via a chloronium ion-
induced condensation Fig. (18).[138] 
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Fig. (18). Hypothetic biogenesis of hapalindole and fischerindole L from 3-
((Z)-2-isocyanovinyl)indole as suggested by Moore and coworkers.[138,139] 
 
This biosynthetic proposal is fostered by the isolation of a hapalindole isomer 
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and hapalindole L by electrophilic aromatic substitution. Interestingly, the formation 
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the biogenetic precursor to the hapalindole and fischerindole families of natural 
products. 
 Fig. (19). The welwitindolines, structurally interesting members of the 
hapalindole series of natural products..[139]  
 
 
Another derivative of the hapalindole series are the welwitindolinones, 
isolated from Hapalosiphon weilwitschi Fig. (19).[139] These compounds are 
presumed as responsible for some of the interesting biological properties of these 
strains of blue-green algae such as multiple-drug-resistance reversing activity 
combined with insecticidal properties. Clearly, welwitindoline A isonitrile is derived 
from the parent structure but contains a unique cyclobutane oxindole core. Several 
derivatives were isolated including rearranged ketones such as N-
methylwitindolinone C isothiocyanate.[139] 
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Fig. (20). Biogenetic hypothesis for the formation of welwitindolinone A 
isonitrile from the isolated intermediate, epi-hapalindole E.[139] 
 
The biosynthesis of welwitindoline can be explained by a common 
intermediate, epi-hapalindole E, derived from 3-((Z)-2-isocyanovinyl)indole as 
discussed above Fig. (20). Oxidation and tautomerization would furnish an indoline 
intermediate, which could undergo the formation of the cyclobutane oxindole core 
welwitindoline. The exact molecular mechanism of the biogenesis, however, 
remains to be elucidated. 
Another class of important indole derived metabolites are the tjipanazoles 
Fig. (21), isolated from Tolypothrix tjipanasensis.[141] These compounds share the 
same indolo[2,3-a]carbazole framework as other bioactive compounds such as 
staurosporine,[142-144] rebeccamycin (antitumor)[145,146] or the synthetic enzastaurin 
(LY317615, anti diabetes).[147,148] Unlike these derivatives from actinomycetes or slime 
molds, the tjipanazoles generally lack the pyrrolo[3,4-c] ring. The indolo[2,3-
a]carbazole scaffold of the tjipanazoles is chlorinated to a varying degree and is 
glycosylated with 6-deoxy-D-gulose (Tjipanazole A1, C1, C2 and G1) and L-
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rhamnose (tjipanazoles A2, C3, C4 and G2). The biological activity of these 
compounds is characterized by antifungal properties, especially against 
phytopathogenic fungi such as rice blast and leaf rust wheat infections. The 
tjipanazole show only very weak activity against leukemia and solid tumor cell lines 
and no protein kinase C inhibition up to 10-6 M concentration. This is in sharp 
contrast to staurosporin/rebeccamycin, which is both an antitumor agent and a 
protein kinase C inhibitor.[143,145,146] The difference in biological activity is explained by 
the pyrrolo[3,4-c] ring of rebeccamycin and analogs, which is essential for their 
powerful biological properties. 
Fig. (21). Tjipanazole, metabolites from Tolypothrix tjipanasensis. 
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indoloquinones, calothrixin A and B, were isolated and their structure determined 
Fig. (22).[149] These compounds contain an indolo[3,2-j]phenanthridine skeleton, 
which is unprecedented in other natural products.  They display nanomolar activity 
against P. falciparum with IC50 values around 100 nM. Calothrixin B was found to be 
less active than the N-oxide (58 nM vs. 180 nM), but still retained sub micromolar 
activity. The well-known antimalarial agent chloroquine displayed an IC50 value of 83 
nM. These indoloquinoline metabolites also inhibit the growth of HeLa cancer cell 
lines, with an IC50 of 40 nM was measured for calothrixin A. 
 Fig. (22). Calothrixin A and B, antitumor antimalarial quinones from Calothrix 
sp. 
 
Cyanobacteria populate many different habitats. In particular, they evolved 
either to cope with little sunlight (i.e. Planktothrix rubescens lives 10-12 m below 
water surface) to being exposed to bright sunlight. In particular the latter case 
requires epilithic cyanobacteria to deal with an overexposure to UV radiation.[150,151] 
For example, on so-called inselbergs, isolated mountains surrounded by the sea, a 
unique vegetation occurs.[152] As there are no higher plants found for example on the 
Mitaraka inselberg in French Guyana, epilithic cyanobacteria, forming thick mats in 
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polysaccharide matrices, are supposed to be the only living organisms under 
intense solar radiation.[152] In order to meet this challenge, such cyanobacteria 
produce polyconjugated indole pigments as suncreens. One of these pigments, 
scytonemin, was reported over 100 years ago, but the structure was only 
characterized in 1993 Fig. (23).[153] It contains a dimeric structure probably derived of 
tryptophan and polyketide biosynthetic pathways. Later, a postulated intermediate, 
nostodione was isolated from a Nostoc species.[154] Nostodione, which was also 
obtained in a different study by ozonolysis of scytonemin,[153]  could be reductively 
dimerized to the dimeric parent structure, scytonemin. Another indole, 
prenostodione, was isolated and postulated to serve as precursor to nostodione.[155] 
However, another possibility of its formation could also be oxidation of the dione 
fragment of nostodione in the course of the isolation procedure. 
 Fig. (23). Cyanobacterial pigments from Scytonema sp (scytonemin[153]), 
Nostoc commune (nostodione[154]) and Nostoc sp (prenostodione[155]). 
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The carbolinium alkaloid nostocarboline was isolated from the freshwater 
cyanobacterium Nostoc 78-12A, its structure characterized and synthesized Fig. 
(24). [156] This quaternary compound contains a chlorine atom, which is unusual for a 
freshwater metabolite. Nostocarboline is a potent cholinesterase inhibitor, which is 
an enzyme targeted in the treatment of Alzheimer!s disease. In a subsequent 
publication, nostocarboline was shown to be an efficient algicide, inducing rapid 
killing of both prokaryotic and eukaryotic photosynthetic organisms. [157] However, 
nostocarboline was not active against normal non-photosynthetic pathogenic 
bacteria and fungi pointing to a potential inhibition in photosynthesis. In order to 
broaden the activity, the natural product hybrid[110], between the known antibacterial 
agent ciprofloxacin and nostocarboline was prepared. This compound shows a 
broad and unprecedented spectrum of activity thus combining the biological activity 
of both fragments.  
Fig. (24). Nostocarboline, a natural carbolinium compound, and a synthetic 
natural product hybrid. 
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5. Protease inhibitors 
Another important class of cyanobacterial metabolites consists of protease 
inhibitors Fig. (25).[158,159] These depsipeptides are characterized by an 
aminohydroxypiperidone (Ahp) unit, a N-methylated amino acid, a threonine, where 
the lactone ring is formed, and an attached peptidic side-chain, which is often 
terminated by either hydrophobic fatty acids or polar acids. Up to now, many of 
these depsipeptides have been isolated from cyanobacteria. One of the first 
members described in the literature are the cyanopeptolins A-D[160] featuring basic 
amino acid (Arg in Cyanopeptolin A, Lys in Cyanopeptolin B, N-Me-Lys in 
Cyanopeptolin, N,N-Dime-Lys in Cyanopeptolin), Ahp, N-Me-Phe as well as a 
terminal hexanoic acid.  
 Fig. (25). Cyanopeptolin A isolated from Microcystis PCC 7806.[160] 
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seemingly defenseless animals are only attacked by certain carnivorous predators, 
which is attributed to a very powerful chemical defense system of the sea slugs.  
These secondary metabolites are now thought to originate from the dietary sources 
of Dolabella such as cyanobacteria. Further support to this hypothesis is given by 
the structural similarity of dolastatin 13 to cyanopeptolins.[162] 
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Table (1). Structure/activity relationships for cyanobacterial depsipeptides 
against chymotrypsin and trypsin. 
 
Depsipeptide Ref. Xaa Yaa Zaa Chymotrypsin 
IC50 (µM) 
Trypsin 
IC50 (µM) 
Micropeptin 88-N [163] Tyr Val Ile 15 ni 
Micropeptin SF909 [164] Gln Leu Ile 5.0 ni 
Micropeptin SD1002 [165] Trp Ile Val 3.2 ni 
Micropeptin T-1 [166] Tyr Phe Val 3.0 ni 
Micropeptin SD979 [165] Tyr Ile Val 2.5 ni 
Micropeptin 88-Y [163] Tyr Val Ile 1.3 ni 
Cyanopeptolin 963A [167] Tyr Leu Val 0.9 ni 
Planktopeptolin BL1125 [168] Leu Thr Ile 0.8 ni 
Nostopeptin BN920 [169] Leu Phe Val 0.11 ni 
Cyanopeptolin 954 [170] Leu Phe Val 0.0044 ni 
Micropeptin T-20 [171] Tyr Phe Ile 0.0025 ni 
Micropeptin SD944 [165] Lys Ille Val ni 8.5 
Micropeptin SD999 [165] Arg Ile Val ni 4 
Micropeptin 90 [172] Arg Phe Val ni 2.5 
Cyanopeptolin S [173] Arg Ile Ille ni 0.2 
Micropeptin T-2 [166] Lys Phe Val ni 0.1 
Micropeptin A [174] Lys Leu Val ni 0.07 
Oscillapeptin F [175] Hca Ile Ile ni 0.2 
A90720A [176] Arg Leu Val ni 0.01 
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As over twenty of these depsipeptides were isolated from cyanobacterial 
sources, structure/activity relationships on their inhibitory action can be performed. 
In table (1), a selection of these compounds is given, with the variable amino acids, 
Xaa, Yaa and Zaa highlighted. Several requirements for activity become evident: 
a. The key residue for protease inhibition consists of the 
aminohydroxypiperidone residue. This amino acid is conserved for all 
these depsipeptides. 
b. All active compounds share a 19-membered lactone ring, with the amino 
acid Zaa acylates the !-OH group of Thr 
c. The selectivity for chymotrypsin is dictated by a hydrophobic amino acid 
adjacent to Ahp, mostly consisting of Tyr or Leu, with Gln and Trp only 
found once. The selectivity for trypsin is achieved by basic amino acids 
such as Arg or Lys. An exception is apparently oscillapeptin F with the 
highly unusual Hca amino acid. 
d. The range of activities is rather broad, spanning three orders of 
magnitude against chymotrypsin and four orders of magnitude for 
trypsin. The most potent derivatives are micropeptin T-20 (IC 50 = 2.5 
nM against chymotrypsin) and A90720A (IC50 = 10 nM against trypsin). 
The mode of action of the potent trypsin inhibitor A90720A[176] can be 
understood by inspection of its crystal structure complex with bovine trypsin Fig. 
(26).[177] Several interesting features can be observed. The arginine side chains 
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occupies trypsin!s deep and narrow specificity pocket, and the terminal guanidinium 
group tightly binds to Asp189 and Ser 190 at the end of the pocket. If A90720A were 
a trypsin substrate, the arginine carbonyl group would be attacked by the Ser OH 
group of the catalytic triad. Whereas the CO group of the Arg of A90720A points in 
the oxyanion hole, the Ser-His part of the catalytic triad are 2.77 Å away from the 
CO of the inhibitor. This distance combined with the strong and defined binding of 
the Ahp residue within the inhibitor leading to a well-defined cyclic conformation, 
inhibits the enzymatic action. Additional binding energy is delivered by the 
hydrophobic region of A90720A involving N-Me-Tyr and a Leucine residue. The Ahp 
residue is essential for the inhibitory action by the transannular hydrogen bonds to 
the Val residue, which determined the binding conformation and thus prevent 
dissociation. The authors of this structural biology work stated that replacement of 
the cyclic Leu residue by and aromatic group will lead to even greater inhibitory 
potency. 
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Fig. (26). Part of the X-Ray crystal structure of the A90720A/bovine trypsin 
complex (protein data bank: 1TPS).)[177]  
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6. Conclusion 
This review gave an overview of the large variety of different cyanobacterial 
metabolites featuring polyketide, alkaloid, peptides and terpene fragments and any 
combination thereof. Whereas some metabolites are of general concern due to their 
toxicity such as microcystins, saxitoxins or anatoxins, other display significant 
pharmaceutical potential as “drugs from the sea” like the cryptophycins. Some of 
these compounds might be produced for deterrence purposes or to render 
cyanobacteria unattractive as a food source for grazer (by strong protease 
inhibitors). Other compounds that act as iron chelators such as anachelin or as 
pigments (scytonemin) have other functions of vital interest to cyanobacteria 
populating habitats with extreme conditions such as bare rocks or the open ocean. 
All these metabolites demonstrate how small molecules can secure evolutionary 
advantage of the producing organisms (in this case cyanobateria) to survive in 
vastly different habitats. Moreover, these fascinating structures combined with 
powerful biological activities are inspiration to the chemist for the understanding of 
natural phenomena on a molecular level and for the development of molecular 
solution to the problems our society faces today.  
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